TuHURA Biosciences, Inc. HURA

NAS: HURA | ISIN: US8989201038 2/04/2026

1,410 USD (-12,96%)

(-12,96%) 2/04/2026

Grafiek TuHURA Biosciences, Inc.

Grafiek TuHURA Biosciences, Inc.

1 dag1d -12,96%
1 week1w -18,50%
1 maand1m -14,02%
3 maanden3m 91,78%
6 maanden6m -43,37%
1 jaar1j -58,28%
5 jaar5j -86,57%

TuHURA Biosciences, Inc. in het nieuws

Toon enkel gratis nieuws

1 april 2026 · TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update · Persbericht

23 maart 2026 · Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers · Persbericht

27 februari 2026 · TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

24 februari 2026 · TuHURA Biosciences Announces Participation in Upcoming Investor Conferences · Persbericht

17 februari 2026 · TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers · Persbericht

12 februari 2026 · TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference · Persbericht

2 februari 2026 · TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma · Persbericht

15 december 2025 · TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone · Persbericht

11 december 2025 · TuHURA Biosciences Provides Corporate Update Following Recent Financing · Persbericht

9 december 2025 · TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe